- Home
- AVIR vs GIW Comparison
AVIR vs GIW Comparison
Compare AVIR & GIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$5.12
Company Overview
Basic Information| Metric | AVIR | GIW |
|---|---|---|
| Founded | 2012 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.1M | 371.3M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | AVIR | GIW |
|---|---|---|
| Price | $5.12 | $10.18 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.42 | N/A |
| AVG Volume (30 Days) | ★ 280.0K | 75.9K |
| Earning Date | 11-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.87 | $9.87 |
| 52 Week High | $6.45 | $10.18 |
Technical Indicators
Market Signals| Indicator | AVIR | GIW |
|---|---|---|
| Relative Strength Index (RSI) | 44.38 | 68.24 |
| Support Level | $5.09 | $10.08 |
| Resistance Level | $5.76 | N/A |
| Average True Range (ATR) | 0.21 | 0.01 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 23.45 | 100.00 |
Price Performance
Historical Comparison AVIR
GIW
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About GIW GigCapital8 Corp. Class A Ordinary Shares
GigCapital8 Corp is a blank check company.